Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.57 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.51 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | BCHE | P06276 | 2/20 | 0.51 |
| ▸ | TYR | P14679 | 2/20 | 0.51 |
| ▸ | ACHE | P22303 | 2/20 | 0.51 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL140947 | 1.00 | TSHR (1.00) | TSHRBLMNPSR1CYP3A4NFKB1 | |
| SCHEMBL134326 | 1.00 | TSHR (1.00) | TSHRBLMNPSR1CYP3A4NFKB1 | |
| SCHEMBL10085823 | 1.00 | TSHR (1.00) | TSHRBLMNPSR1CYP3A4NFKB1 | |
| SCHEMBL28717780 | 0.98 | TSHR (0.97) | TSHRBLMNPSR1CYP3A4NFKB1 | |
| SCHEMBL10784788 | 0.98 | TSHR (0.97) | TSHRBLMNPSR1CYP3A4NFKB1 | |
| SCHEMBL20566321 | 0.95 | BLM (0.91) | TSHRBLMNPSR1CYP3A4NFKB1 | |
| SCHEMBL9065486 | 0.94 | TSHR (0.88) | TSHRBLMNPSR1CYP3A4NFKB1 | |
| SCHEMBL20566322 | 0.91 | TSHR (0.83) | TSHRBLMNPSR1CYP3A4NFKB1 | |
| SCHEMBL29395159 | 0.89 | TSHR (0.79) | TSHRBLMNPSR1CYP3A4NFKB1 | |
| SCHEMBL503700 | 0.86 | NPSR1 (0.76) | TSHRBLMNPSR1CYP3A4GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024127352-A1 | FORMULATION COMPRISING VANILLOID POLYPHENOLS SUPPORTED ON LAMELLAR SOLIDS TO REDUCE PLASMA CGRP LEVELS AND ITS APPLICATIONS | PROLABIN & TEFARM S.R.L. (IT) | 2024-06-20 | — | — | WO | claimed |
| US-20240398771-A1 | TREATMENT OF SCLERODERMA AND RAYNAUD'S SYNDROME | AISA PHARMA, INC. | 2024-12-05 | — | — | US | disclosed |
| CN-114354938-B | Vanilla mandelic acid homogeneous enzyme immunoassay reagent based on brominated derivatives and preparation method thereof | 苏州博源医疗科技有限公司 | 2024-11-29 | — | — | CN | disclosed |
| US-20240366582-A1 | TREATMENT OF RAYNAUD'S DISEASE | AISA PHARMA, INC. | 2024-11-07 | — | — | US | disclosed |
| US-20240358692-A1 | TREATMENT OF SCLERODERMA | AISA PHARMA, INC. | 2024-10-31 | — | — | US | disclosed |
| US-20240358693-A1 | METHODS OF TREATING PAIN | AISA PHARMA, INC. | 2024-10-31 | — | — | US | disclosed |
| WO-2024127352-A1 | FORMULATION COMPRISING VANILLOID POLYPHENOLS SUPPORTED ON LAMELLAR SOLIDS TO REDUCE PLASMA CGRP LEVELS AND ITS APPLICATIONS | PROLABIN & TEFARM S.R.L. (IT) | 2024-06-20 | — | — | WO | disclosed |
| US-11841373-B2 | Information processing apparatus, method for controlling information processing apparatus, and program | CANON KABUSHIKI KAISHA (JP) | 2023-12-12 | — | — | US | disclosed |
| CN-117092263-A | Free catecholamine and metabolite detection kit, determination method and application | 合肥歆智医疗器械有限公司 | 2023-11-21 | — | — | CN | disclosed |
| CN-115746320-B | Synthesis method and application of lanthanide series metal organic framework material Eu-MOF | 浙江省人民医院 | 2023-08-08 | — | — | CN | disclosed |
| US-20110045069-A1 | PRECURSOR COMPOUNDS OF SWEET TASTE RECEPTOR ANTAGONISTS FOR THE PREVENTION OR TREATMENT OF DISEASE | SYMRISE GMBH CO. KG (DE) | 2011-02-24 | — | — | US | disclosed |
| US-6921758-B2 | Amino acid derivatives | ASTRAZENECA AB (SE) | 2005-07-26 | — | — | US | disclosed |
| US-20040087647-A1 | NEW AMINO ACID DERIVATIVES | ASTRAZENECA AB | 2004-05-06 | — | — | US | disclosed |
| US-6617320-B2 | Protease inhibitor; anticoagulants | ASTRAZENECA AB (SE) | 2003-09-09 | — | — | US | disclosed |
| EP-0836615-B1 | NEW THROMBIN INHIBITORS, THEIR PREPARATION AND USE | ASTRAZENECA AB (SE) | 2003-04-23 | — | — | EP | disclosed |
| US-20020042396-A1 | Amino acid derivatives | ASTRA AB | 2002-04-11 | — | — | US | disclosed |
| US-6337343-B1 | TREATMENT OF THROMBOSIS WITH ANTICOAGULANTS | ASTRAZENECA AB (SE) | 2002-01-08 | — | — | US | disclosed |
| US-6051568-A | Thrombin inhibitors, their preparation and use | ASTRA AKTIEBOLAG (SE) | 2000-04-18 | — | — | US | disclosed |
| EP-0836615-A1 | NEW THROMBIN INHIBITORS, THEIR PREPARATION AND USE | Astra Aktiebolag (SE) | 1998-04-22 | — | — | EP | disclosed |
| WO-1997002284-A1 | NEW THROMBIN INHIBITORS, THEIR PREPARATION AND USE | ASTRA AKTIEBOLAG (SE) | 1997-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042396-A1 | Amino acid derivatives | F2, SERPINC1, ARGLU1 | TSHR 543/4885BLM 2731/4885NPSR1 361/4885 |
| US-20040087647-A1 | NEW AMINO ACID DERIVATIVES | F2, ANPEP, PEPD | TSHR 956/4885BLM 3526/4885NPSR1 309/4885 |
| US-20110045069-A1 | PRECURSOR COMPOUNDS OF SWEET TASTE RECEPTOR ANTAGONISTS FOR THE PREVENTION OR TREATMENT OF DISEASE | TAS1R2, TAS2R5, TAS2R1 | TSHR 73/4885BLM 4717/4885NPSR1 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.